Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

• Main Authors: Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-06-01
• Series: Pharmacogenomics and Personalized Medicine
• Subjects: abiraterone; androgens; castration resistance prostate cancer; cyp17a1; cyb5a
• Online Access: https://www.dovepress.com/association-between-cyp17a1-cyb5a-polymorphisms-and-efficacy-of-abirat-peer-reviewed-article-PGPM

Xiang Wu,1,2 Qing-Jiang Xu,1,2 Ping-Zhou Chen,1,2 Chen-Bo Yu,1,2 Lie-Fu Ye,1,2 Tao Li1,2 1Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of ChinaCorrespondence: Tao Li Tel [phone]Email [e-mail]: The purpose of this study was to investigate the association between single nucleotide polymorphisms (SNPs) of CYP17A1, CYB5A and the efficacy of abiraterone acetate treatment in patients with castration-resistant prostate cancer (CRPC).Patients and Methods: Data were collected from 58 CRPC patients who had been treated with abiraterone acetate/prednisone (AA/P). The SNPs rs743572 and rs10883783 on CYP17A1 and SNPs rs1790834 and rs1790858 on CYB5A were assayed, and their relationship with prostate-specific antigen (PSA) response in patients after AA/P treatment, overall survival (OS) and progression-free survival (PFS) were analyzed by logistic regression, Cox regression, Kaplan–Meier and Log rank analyses.Results: The SNP rs1790834 on CYB5A showed significant association with PSA response in CRPC patients treated with AA/P (P < 0.05), but rs743572, rs10883783 and rs1790858 did not. The rs1790834 variant significantly decreased both PFS and OS (P < 0.05).Conclusion: The CYB5A rs790834 genotype is a novel SNP related to CRPC and may be used as a biomarker for CRPC treatment.Keywords: abiraterone, androgens, castration-resistant prostate cancer, CYP17A1, CYB5A